NL
GSK icon

NKCFO LLC’s GSK GSK Stock Holding History

NKCFO LLC’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,800
Closed -$3.69M – 110
2026
Q1 		$3.69M Hold
66,800
– – 1.09% 27
2025
Q4 		$3.28M Buy
+66,800
New +$3.12M 0.95% 25
2022
Q4 		– Sell
-218,200
Closed -$6.42M – 99
2022
Q3 		$6.42M Buy
218,200
+2,600
+1% +$98.5K 2.97% 16
2022
Q2 		$11.7M Hold
215,600
– – 4.13% 5
2022
Q1 		$11.7M Hold
215,600
– – 3.65% 7
2021
Q4 		$11.9M Hold
215,600
– – 3.82% 8
2021
Q3 		$10.3M Buy
+215,600
New +$10.8M 3.45% 8

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

NKCFO LLC's GSK Position: Q2 2026 in Review

NKCFO LLC sold out of GSK (GSK) in Q2 2026, closing a stake of 66,800 shares — an estimated $3.69M sold.

NKCFO LLC first reported a position in GSK in Q3 2021 and held it in 7 quarters. The position peaked at $11.9M in Q4 2021. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • NKCFO LLC reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • NKCFO LLC sold 66,800 GSK shares in Q2 2026, an estimated $3.69M.
  • NKCFO LLC first reported a position in GSK in Q3 2021 and held it in 7 quarters.
  • NKCFO LLC's GSK position peaked at $11.9M in Q4 2021.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on NKCFO LLC's 13F filing for Q2 2026, filed 13 Aug 2026.